Hoth Therapeutics Announces Key Opinion Leader Event to Present Interim Phase 2 Trial Results for HT-001, a Novel Therapy for Cancer-Related Skin Toxicities

Reuters

06/23

<a href="https://laohu8.com/S/HOTH">Hoth Therapeutics</a> Announces Key Opinion Leader Event to Present Interim Phase 2 Trial Results for HT-001, a Novel Therapy for Cancer-Related Skin Toxicities

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, announced a virtual Key Opinion Leader $(KOL)$ event scheduled for June 24, 2025, at 3:30PM EST. The event will focus on HT-001, a novel topical therapeutic developed to address skin toxicities induced by EGFR inhibitors in cancer patients. The presentation will include interim results from an ongoing Phase 2 trial, with insights from specialists in derm-oncology and dermatology, Jonathan Hale Zippin M.D., Ph.D., and Adam Friedman M.D., F.A.A.D. This event will highlight the recent clinical progress of HT-001 and its potential to redefine supportive care standards for oncology patients. The event can be accessed through the provided Zoom link.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15617) on June 23, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2545118344"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545118344\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545118344?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545118344","market":"us","top_or_hot":-1,"title":"Hoth Therapeutics Announces Key Opinion Leader Event to Present Interim Phase 2 Trial Results for HT-001, a Novel Therapy for Cancer-Related Skin Toxicities","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> Announces Key Opinion Leader Event to Present Interim Phase 2 Trial Results for HT-001, a Novel Therapy for Cancer-Related Skin Toxicities\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, announced a virtual Key Opinion Leader <a href=\"https://laohu8.com/S/KOL\">$(KOL)$</a> event scheduled for June 24, 2025, at 3:30PM EST. The event will focus on HT-001, a novel topical therapeutic developed to address skin toxicities induced by EGFR inhibitors in cancer patients. The presentation will include interim results from an ongoing Phase 2 trial, with insights from specialists in derm-oncology and dermatology, Jonathan Hale Zippin M.D., Ph.D., and Adam Friedman M.D., F.A.A.D. This event will highlight the recent clinical progress of HT-001 and its potential to redefine supportive care standards for oncology patients. The event can be accessed through the provided <a href=\"https://laohu8.com/S/ZM\">Zoom</a> link.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15617) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Therapeutics Announces Key Opinion Leader Event to Present Interim Phase 2 Trial Results for HT-001, a Novel Therapy for Cancer-Related Skin Toxicities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Therapeutics Announces Key Opinion Leader Event to Present Interim Phase 2 Trial Results for HT-001, a Novel Therapy for Cancer-Related Skin Toxicities\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-23 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> Announces Key Opinion Leader Event to Present Interim Phase 2 Trial Results for HT-001, a Novel Therapy for Cancer-Related Skin Toxicities\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hoth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, announced a virtual Key Opinion Leader <a href=\"https://laohu8.com/S/KOL\">$(KOL)$</a> event scheduled for June 24, 2025, at 3:30PM EST. The event will focus on HT-001, a novel topical therapeutic developed to address skin toxicities induced by EGFR inhibitors in cancer patients. The presentation will include interim results from an ongoing Phase 2 trial, with insights from specialists in derm-oncology and dermatology, Jonathan Hale Zippin M.D., Ph.D., and Adam Friedman M.D., F.A.A.D. This event will highlight the recent clinical progress of HT-001 and its potential to redefine supportive care standards for oncology patients. The event can be accessed through the provided <a href=\"https://laohu8.com/S/ZM\">Zoom</a> link.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15617) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL3vHYH9:1","article_id":"2545118344","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545118344","pubTimestamp":1750680209,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hoth Therapeutics Announces Key Opinion Leader Event to Present Interim Phase 2 Trial Results for HT-001, a Novel Therapy for Cancer-Related Skin Toxicities. Hoth Therapeutics, Inc. , a clinical-stage biopharmaceutical company, announced a virtual Key Opinion Leader  event scheduled for June 24, 2025, at 3:30PM EST. The event will focus on HT-001, a novel topical therapeutic developed to address skin toxicities induced by EGFR inhibitors in cancer patients. The presentation will include interim results from an ongoing Phase 2 trial, with insights from specialists in derm-oncology and dermatology, Jonathan Hale Zippin M.D., Ph.D., and Adam Friedman M.D., F.A.A.D. This event will highlight the recent clinical progress of HT-001 and its potential to redefine supportive care standards for oncology patients. The event can be accessed through the provided Zoom link.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","HOTH":"Hoth Therapeutics"},"translate_title":"Hoth Therapeutics宣布举办关键意见领袖活动，展示HT-001（一种治疗癌症相关皮肤毒性的新疗法）的中期2期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOTH":0.9},"content_text":"Hoth Therapeutics Announces Key Opinion Leader Event to Present Interim Phase 2 Trial Results for HT-001, a Novel Therapy for Cancer-Related Skin Toxicities\n    \n\n        Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, announced a virtual Key Opinion Leader $(KOL)$ event scheduled for June 24, 2025, at 3:30PM EST. The event will focus on HT-001, a novel topical therapeutic developed to address skin toxicities induced by EGFR inhibitors in cancer patients. The presentation will include interim results from an ongoing Phase 2 trial, with insights from specialists in derm-oncology and dermatology, Jonathan Hale Zippin M.D., Ph.D., and Adam Friedman M.D., F.A.A.D. This event will highlight the recent clinical progress of HT-001 and its potential to redefine supportive care standards for oncology patients. The event can be accessed through the provided Zoom link.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hoth Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15617) on June 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}